What is the market valuation of the cancer and tumor biomarker-based assay market?

As of 2027, the market size of cancer and tumor biomarker-based assay is valued at USD 14.15 billion.

What is the projected value of the cancer and tumor biomarker-based assay industry by 2036?

Cancer and Tumor Biomarker-based Assay Market size was valued at USD 12.93 billion in 2026 and is anticipated to grow at a 10.92% CAGR from 2027 to 2036, attaining USD 36.45 billion by 2036.

How is personalized medicine accelerating adoption of cancer biomarker-based assays?

Growing emphasis on individualized treatment is increasing demand for biomarker testing that supports earlier detection, molecular characterization, treatment selection, and response assessment, strengthening its role in clinical decision-making.

How are assay innovations expanding the commercial application of tumor biomarker testing?

Advances in molecular detection, multiplex analysis, automation, and data interpretation are improving sensitivity and workflow efficiency, enabling broader use of comprehensive biomarker testing across research and clinical settings.

Which end-use segment dominates the cancer and tumor biomarker-based assay market?

Hospitals and cancer centers accounted for 47% of the market in 2026, supported by oncology expertise, advanced diagnostic infrastructure, and growing integration of biomarker assays into clinical workflows.

Which cancer type segment is expected to grow fastest?

Breast cancer held a 25.3% share in 2026 and is projected to grow fastest, driven by increasing biomarker testing for tumor characterization, personalized treatment selection, and response assessment.

Why does North America lead the cancer and tumor biomarker-based assay market?

North America accounted for 44.1% of the market in 2026, supported by advanced oncology research, established diagnostic infrastructure, precision medicine adoption, and increasing use of biomarker assays for treatment selection and disease monitoring.

What is driving the rapid growth of biomarker-based cancer assays in Asia Pacific?

Asia Pacific is the fastest-growing region, driven by rising cancer incidence, expanding oncology services, improved laboratory infrastructure, and increasing adoption of molecular diagnostics and precision medicine for earlier, more targeted cancer care.

Who holds a significant market share in the cancer and tumor biomarker-based assay landscape?

Major players in the cancer and tumor biomarker-based assay market include Roche (Switzerland), Thermo Fisher Scientific (USA), Agilent Technologies (USA), Abbott (USA), Bio-Rad Laboratories (USA), Qiagen (Netherlands), Illumina (USA), Siemens Healthineers (Germany), Becton Dickinson (USA), Merck KGaA (Germany).